## §SELF — miscsubjects portable reference **Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next. **This widget:** `article_bundle` — **LLM article bundle** Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. - **article slug:** `slu-pp-332` - **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest - **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system. - **read:** https://miscsubjects.com/api/articles/slu-pp-332/bundle?format=markdown ### Logical proof (verify each step) 1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution 2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/slu-pp-332/sources 3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol 4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow 5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex 6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map ### Related features (explains other parts of the system) - **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/slu-pp-332/topology - **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/slu-pp-332/voxels - **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/slu-pp-332/prompts - **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node. - **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/slu-pp-332/voxels - **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest ### Full index - JSON: https://miscsubjects.com/api/articles/system-map - Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown ### §STRUCTURE This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure ### §INTEGRITY Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you. ### §GAUNTLET Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted. *Not medical advice. Tier-honest. Cite claim/source ids.* --- # miscsubjects article bundle > Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest. ## MASTHEAD - **identity:** `slu-pp-332` v3 · content_hash `5c9dfd652643d650…` · thread_head genesis - **thesis (c1):** SLU-PP-332 is an agonist of the estrogen-related receptors ERRα, ERRβ and ERRγ, with its highest potency at ERRα. - c2 [mechanistic/active] Its discovery paper describes it as a chemical tool with sufficient pharmacokinetic properties to be used in vivo, not as a drug candidate. - c3 [animal/active] In mice, SLU-PP-332 increased the proportion of type IIa oxidative skeletal muscle fibres and enhanced exercise capacity. - c4 [animal/active] In diet-induced obese and ob/ob mice it raised energy expenditure and fatty acid oxidation, reduced fat mass accumulation, and improved insulin sensitivity. - c5 [human/active] No human study of SLU-PP-332 has been published: no phase I, no safety study, no pharmacokinetic run, so its half-life and oral bioavailability in people are un - c6 [animal/active] Pan-ERR agonists improved heart failure in animal models by enhancing cardiac fatty acid metabolism and mitochondrial function. - c7 [animal/active] ERR agonism also reversed mitochondrial dysfunction and inflammation in the aging kidney in animal models, making the mechanism systemic rather than confined to - c8 [mechanistic/active] Exercise mimetic describes activation of a shared genetic programme, not equivalence to training: the compound does nothing for bone loading, tendon strength, c - **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes - **standing objections:** 0 open → https://miscsubjects.com/api/articles/slu-pp-332/discourse - **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key - **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/slu-pp-332/discourse · https://miscsubjects.com/api/protocol ## Article - **slug:** `slu-pp-332` - **title:** SLU-PP-332 is a chemical tool that switches on the endurance-training programme in muscle - **url:** https://miscsubjects.com/a/slu-pp-332 - **register:** canonical - **updated:** 2026-08-05T09:39:20.822Z - **tags:** slu-pp-332, ERR agonist, exercise mimetic, mitochondria, preclinical ## Body SLU-PP-332 is a small molecule that turns on a genetic programme normally switched on by hard aerobic exercise. In mice it does roughly what a run does to muscle. It has never been given to a human being in a published study, and it was not built to be a drug. That last part matters more than anything else about it, so it goes first. The paper that introduced it describes it as a chemical tool: the authors say it "has sufficient pharmacokinetic properties to be used as an in vivo chemical tool." A tool is something you use to find out whether an idea is worth pursuing. It is not a candidate you intend to put in people. Compounds designed as drugs get years of work on absorption, half-life, off-target effects and toxicology before anyone considers a first human dose. SLU-PP-332 got enough of that to survive an experiment in a mouse. ## What ERR is, and why anyone went looking for a molecule that hits it Inside almost every cell in your body there are proteins whose whole job is to switch genes on. They sit in the cell, wait for a signal, and when the signal arrives they bind to DNA and start production of whichever proteins that gene encodes. They are called nuclear receptors, because they work in the nucleus where the DNA is. Three of them are called estrogen-related receptors — ERRα, ERRβ and ERRγ. The name is a historical accident. They look structurally similar to the receptor that oestrogen binds to, which is how they were first identified, but oestrogen does not bind to them and they have nothing to do with sex hormones. They are called "orphan" receptors because nobody has found the natural signal that switches them on. We know what they do without knowing what tells them to do it. What they do is run mitochondria. Mitochondria are the structures inside cells that convert fuel into usable energy, and a muscle cell that has done a lot of endurance work has more of them, and better ones. ERRα in particular controls a large set of genes governing how many mitochondria a muscle has, how well they work, and whether the muscle prefers to burn fat or sugar. When you train for endurance, ERR activity is part of what carries out the resulting change. So the reasoning was direct: if ERR carries out the adaptation, a molecule that activates ERR should produce the adaptation without the training. That reasoning was easier to state than to act on. The paper introducing SLU-PP-332 says why: "although ERRβ/γ agonists have been designed, there have been significant difficulties in designing compounds with ERRα agonist activity." ERRα was the one that mattered most and the one nobody could hit. SLU-PP-332's actual achievement is that it hits all three, "but has the highest potency for ERRα." ## What happened in the mice Two studies carry almost all of the evidence. The first, in *ACS Chemical Biology* in 2023, established what the molecule does. In cells it "increases mitochondrial function and cellular respiration in a skeletal muscle cell line." In animals it changed the muscle itself: "When administered to mice, SLU-PP-332 increased the type IIa oxidative skeletal muscle fibers and enhanced exercise capacity." Type IIa fibres are the intermediate kind — faster than the slow endurance fibres, far more fatigue-resistant than the fast explosive ones, and rich in mitochondria. Growing the type IIa share is one of the specific things endurance training does. The compound produced that change in animals that had not trained. The second, in the *Journal of Pharmacology and Experimental Therapeutics* in January 2024, asked whether that translated into metabolic benefit in obese animals. Diet-induced obese mice and ob/ob mice — a strain genetically unable to produce leptin, so they overeat and become obese — were given the compound. The result, in the paper's words: "SLU-PP-332 administration mimics exercise-induced benefits on whole-body metabolism in mice including increased energy expenditure and fatty acid oxidation. These effects were accompanied by decreased fat mass accumulation. Additionally, the ERR agonist effectively reduced obesity and improved insulin sensitivity in models of metabolic syndrome." Read what that says and what it does not. It says energy expenditure went up, fat oxidation went up, fat accumulation went down, and insulin sensitivity improved. It says this in mice. The paper's own significance statement keeps the qualifier attached: the compound "holds promise as a therapeutic to treat metabolic diseases by decreasing fat mass in mouse models of obesity." The figures that circulate — 70 percent longer running time, 45 percent further, roughly ten times less fat gained, 12 percent body weight lost — come from these studies and from the university's press coverage of them. They are real numbers from real experiments. They are also mouse numbers, and mouse metabolic numbers are among the least reliable predictors of human outcomes in all of pharmacology, because a mouse burns energy at a completely different rate relative to its size and its brown fat behaves differently from an adult human's. ## The heart, and why it cuts both ways There is a third study worth knowing about, and it is the most interesting one, because it points at both the promise and the risk. Published in *Circulation* in January 2024, it tested pan-ERR agonists in heart failure. The title states the finding: "Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function." A failing heart has a characteristic metabolic defect — it loses the ability to burn fat efficiently and falls back on less efficient fuel, which makes the failure worse. Restoring fat oxidation in cardiac muscle is a real therapeutic idea, and in these animal models the ERR agonists did it. That is genuinely good news for the mechanism. It is also the clearest statement available that this compound acts on the heart. Cardiac muscle is dense with mitochondria and dense with ERR. A molecule that reprogrammes mitochondrial metabolism does not confine itself to your quadriceps. In a diseased heart with a known metabolic defect that reprogramming helped. Nobody has published what it does to a structurally normal human heart over months, because nobody has run that study. A fourth study, in the *American Journal of Pathology* in December 2023, found ERR agonism "reverses mitochondrial dysfunction and inflammation in the aging kidney." Same pattern: another organ, another mitochondria-dense tissue, another real effect. The mechanism is systemic. That is the point of it and also the thing to be careful about. ## What "exercise mimetic" does and does not mean The phrase does a lot of work and most of it is misleading, so it is worth taking apart. Exercise is not one thing. A hard hour of aerobic work does at least a dozen distinguishable things to you. It builds mitochondria in the muscles that did the work. It shifts fibre composition toward fatigue resistance. It grows new capillaries into those muscles so more blood reaches them. It improves how sensitively your tissues respond to insulin. It strengthens the heart as a pump, raising the volume it moves per beat. It loads bone and tendon, which is the signal that keeps both dense and strong. It raises brain-derived neurotrophic factor, which is part of why training affects mood and memory. It improves how well the lining of your blood vessels dilates. It clears fat out of the bloodstream after meals. It changes appetite regulation. It improves sleep. And it does all of this in proportion to the work done, in the tissues that did the work, over weeks. SLU-PP-332 addresses the first two of those and touches a third. It builds mitochondria and shifts fibre type, and it raises fat oxidation, which is downstream of the same programme. It does not load your bones. It does not build capillaries into a muscle that never contracted. It does not strengthen the heart as a pump — it changes cardiac metabolism, which is a different thing. It does not improve tendon strength, which is the tissue most likely to be the limiting factor when someone with new metabolic capacity starts training harder. So "exercise mimetic" is accurate in the narrow, technical sense the researchers use it: the compound activates a genetic programme that acute aerobic exercise also activates. It is inaccurate in the sense a reader will take it, which is "does what exercise does." A molecule that grows mitochondria in a sedentary animal is a genuinely interesting result. It is not a substitute for the training and it was never claimed to be, by anyone who did the work. ## Doses, and why the numbers you see are invented The published animal work used doses in the range of tens of milligrams per kilogram, given by injection, over days to weeks. Those are the only real numbers that exist for this compound. Converting an animal dose to a human one is not multiplication. The standard method scales by body surface area rather than weight, because small animals run their metabolism faster relative to their size, and even that method is a rough approximation that assumes you know how fast each species clears the compound. For SLU-PP-332 nobody knows how fast a human clears it, because no human has been given a measured dose and had their blood drawn. Its half-life in people is unknown. Its oral bioavailability in people is unknown. Whether it reaches muscle tissue in a person at any tolerable dose is unknown. Any specific human protocol you find — a milligram figure, a cycle length, a timing relative to training — was written by someone who did not have this information either. That is not a claim that such protocols are dangerous. It is a statement of what they are: guesses presented with the confidence of instructions. ## The interactions nobody can tell you about For most compounds, the interaction section is a list. For this one, the honest content is an explanation of why the list cannot be written. Drug interactions are worked out empirically. You find out which liver enzymes metabolise a compound, then you test it against drugs that use the same enzymes and see whose clearance changes. That work has not been published for SLU-PP-332. So the specific question — does this affect how you process your statin, your thyroid medication, your antidepressant — has no answer, and anyone who gives you one is inventing it. What can be reasoned about is the mechanism, and two things follow from it. Anything else that drives mitochondrial biogenesis or fat oxidation is pushing in the same direction. That includes AMPK activators like metformin and the research compounds in that class, PPAR agonists, thyroid hormone and its analogues, and to a lesser extent the fibrates. Stacking two systemic metabolic reprogrammers without any human data on either is compounding an unknown with an unknown. Anything that stresses the heart deserves particular caution, because the Circulation study established that this mechanism acts on cardiac muscle. That is not a warning that it damages the heart — in a failing heart it helped. It is a statement that the heart is in scope, so stimulants, thyroid excess, and anything that raises cardiac workload are being added to a compound that is already changing how cardiac muscle handles fuel. The mitochondria-dense organs are the ones to watch in principle: heart, kidney, liver, skeletal muscle, brain. Two of the four published studies are about the heart and the kidney specifically, which tells you the mechanism reaches both. ## What is not known, stated plainly There are no human studies. Not a phase I, not a safety study, not a single-dose pharmacokinetic run in volunteers. Every number attached to this compound came out of a mouse or a cell culture dish. There is no human dose. The doses quoted in the research are milligrams per kilogram given to mice, usually by injection. Scaling an animal dose to a human is not arithmetic — it depends on how fast each species clears the compound, and no human clearance data exists. Any specific human protocol you encounter for this compound was invented by whoever wrote it. There is no long-term data in any species. The mouse studies ran for weeks. Nothing is published about a year of exposure in any animal. The obvious theoretical concern has not been tested. Building mitochondria and driving fat oxidation across every tissue that carries ERR — heart, kidney, liver, muscle, brain — is a large systemic intervention. Exercise produces the same adaptations but produces them gradually, locally, in proportion to the work done, and with every other adaptation of training arriving alongside. A drug does not have that self-limiting quality. What happens when you drive the programme continuously and without the training is an open question, not a resolved one. It is not a peptide. It is a small molecule, and the "SLU" in the name is Saint Louis University, where the chemistry was done. It is sold beside peptides and constantly called one. ## How to read the numbers that circulate Four figures come up constantly: 70 percent longer running time, 45 percent further distance, roughly ten times less fat gained, 12 percent of body weight lost. All four trace back to the two studies above and to the university press coverage of them. None is fabricated. Each is worth reading with two things in mind. The first is what the comparison was. "70 percent longer" is against untreated mice in the same experiment, not against trained mice. The question the study answered is "does this compound raise exercise capacity in an animal that has not trained," and the answer was yes. The question it did not ask is "does this compound raise exercise capacity more than training would," which is the question a person considering it is actually asking. The second is the species gap, which for metabolic endpoints specifically is wider than most people assume. A mouse has a resting metabolic rate roughly seven times an adult human's per unit of mass. It carries a proportionally large amount of brown fat, the heat-generating tissue that adult humans have very little of, and brown fat is where a lot of drug-induced energy expenditure in mice actually happens. Mice housed at ordinary laboratory temperature are mildly cold-stressed, which means they are already burning energy to stay warm, and interventions that raise energy expenditure look better under that condition than they do at thermoneutrality. This is not a niche objection. It is the single most common reason obesity compounds that transform mice do nothing in people, and the history of the field is largely a list of them. So the figures are real measurements of a real effect in an animal whose energy metabolism does not work like yours. That is the correct amount of weight to give them: enough to make the mechanism worth pursuing, not enough to predict what happens in a person. ## What it is actually useful for thinking about The honest reason to pay attention to SLU-PP-332 is not that it is a shortcut. It is that it demonstrated something specific and previously unproven: that a single small molecule can switch on a meaningful part of the endurance-training programme in a living animal, including the fibre-type shift, and that doing so improves metabolic disease in that animal. Before this compound, ERRα was considered close to undruggable. That is a real scientific result and it will produce better molecules than this one. What it does not demonstrate is that any of this works in a person, at any dose, with any safety margin. There is no evidence either way, because the experiment has not been done. Anyone treating a mouse chemical tool as an exercise substitute should be clear about what they are actually doing: taking a compound with no human data, no established dose, no safety profile, and a mechanism that acts on every mitochondria-rich organ including the heart. That is not a caution bolted onto the end of an article. It is the accurate description of the compound's position in 2026, and it is the same thing the researchers who made it have said in print. Everything above is what the published record supports. None of it is medical advice, and SLU-PP-332 is sold for research use only, not for human consumption. ## Claims (8) - **c5** [human w=?] No human study of SLU-PP-332 has been published: no phase I, no safety study, no pharmacokinetic run, so its half-life and oral bioavailability in people are unknown. - **c1** [mechanistic w=?] SLU-PP-332 is an agonist of the estrogen-related receptors ERRα, ERRβ and ERRγ, with its highest potency at ERRα. - sources: s1, s3 - **c2** [mechanistic w=?] Its discovery paper describes it as a chemical tool with sufficient pharmacokinetic properties to be used in vivo, not as a drug candidate. - sources: s1 - **c8** [mechanistic w=?] Exercise mimetic describes activation of a shared genetic programme, not equivalence to training: the compound does nothing for bone loading, tendon strength, capillary density or the heart as a pump. - sources: s1 - **c3** [animal w=?] In mice, SLU-PP-332 increased the proportion of type IIa oxidative skeletal muscle fibres and enhanced exercise capacity. - sources: s2 - **c4** [animal w=?] In diet-induced obese and ob/ob mice it raised energy expenditure and fatty acid oxidation, reduced fat mass accumulation, and improved insulin sensitivity. - sources: s4, s5 - **c6** [animal w=?] Pan-ERR agonists improved heart failure in animal models by enhancing cardiac fatty acid metabolism and mitochondrial function. - sources: s6 - **c7** [animal w=?] ERR agonism also reversed mitochondrial dysfunction and inflammation in the aging kidney in animal models, making the mechanism systemic rather than confined to skeletal muscle. - sources: s7 ## Voxel graph (8 atoms · 9 edges) - full graph: https://miscsubjects.com/api/articles/slu-pp-332/voxels ## Article constitution - full: https://miscsubjects.com/api/articles/constitution ## Source ledger (7) - chain valid: yes · head: `3ff096fde160703c` ### s1 · pubmed - title: Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity - url: https://pubmed.ncbi.nlm.nih.gov/36988910/ - summary: Billon et al., ACS Chem Biol 2023: the paper that introduced the compound. Its own description of what SLU-PP-332 is — a chemical tool with enough pharmacokinetics to survive an animal experiment, not a drug candidate. That framing is the single most important fact about it and it comes from the people who made it. - quote: Here, we report the identification of a synthetic ERR pan agonist, SLU-PP-332, that targets all three ERRs but has the highest potency for ERRα. Additionally, SLU-PP-332 has sufficient pharmacokinetic properties to be used as an in vivo chemical tool. - hash: `fb67c9ddf6e5943c` ### s2 · pubmed - title: Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity - url: https://pubmed.ncbi.nlm.nih.gov/36988910/ - summary: SLU-PP-332 in mice: type IIa oxidative fibres and exercise capacity. The core animal result. Type IIa fibres are the fatigue-resistant, mitochondria-rich intermediate type, and growing their share is one of the specific things endurance training does. The compound produced that shift in animals that had not trained. - quote: When administered to mice, SLU-PP-332 increased the type IIa oxidative skeletal muscle fibers and enhanced exercise capacity. - hash: `780d416d0062f20d` ### s3 · pubmed - title: Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity - url: https://pubmed.ncbi.nlm.nih.gov/36988910/ - summary: Why ERRα had resisted every previous attempt. The reason this compound is a real scientific result rather than another metabolic molecule. ERRα is the subtype that governs the muscle programme and it was the one nobody could hit. SLU-PP-332 hits all three with the highest potency at ERRα. - quote: Three ERR subtypes exist (ERRα, β, and γ), and although ERRβ/γ agonists have been designed, there have been significant difficulties in designing compounds with ERRα agonist activity. - hash: `c24e86dd352b0263` ### s4 · pubmed - title: A Synthetic ERR Agonist Alleviates Metabolic Syndrome - url: https://pubmed.ncbi.nlm.nih.gov/37739806/ - summary: Billon et al., J Pharmacol Exp Ther 2024: diet-induced obese and ob/ob mice. This is the study behind every fat-loss figure quoted for this compound. Note what it says and does not say — every measurement is in mice. - quote: SLU-PP-332 administration mimics exercise-induced benefits on whole-body metabolism in mice including increased energy expenditure and fatty acid oxidation. These effects were accompanied by decreased fat mass accumulation. Additionally, the ERR agonist effectively reduced obesity and improved insulin sensitivity in models of metabolic syndrome. - hash: `02b1250b48f99233` ### s5 · pubmed - title: A Synthetic ERR Agonist Alleviates Metabolic Syndrome - url: https://pubmed.ncbi.nlm.nih.gov/37739806/ - summary: The authors’ own significance statement, with its qualifier intact. The qualifier "in mouse models of obesity" is in the authors’ own summary sentence. It is the part that gets dropped when the numbers are repeated. - quote: An estrogen receptor-related orphan receptor agonist, SLU-PP-332, with exercise mimetic activity, holds promise as a therapeutic to treat metabolic diseases by decreasing fat mass in mouse models of obesity. - hash: `bfdc8f44728884d3` ### s6 · pubmed - title: Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function - url: https://pubmed.ncbi.nlm.nih.gov/37961903/ - summary: Xu, Billon et al., Circulation 2024. The most double-edged paper in the set. A failing heart loses the ability to burn fat efficiently, and restoring that is a real therapeutic idea — these agonists did it in animal models. It is also the clearest published statement that this compound acts on cardiac muscle, which is dense with both mitochondria and ERR. Nobody has published what it does to a structurally normal human heart over months. - quote: Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function. - hash: `88a1626f35827fc6` ### s7 · pubmed - title: Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney - url: https://pubmed.ncbi.nlm.nih.gov/37717940/ - summary: Wang et al., Am J Pathol 2023. A fourth organ, a fourth real effect, same pattern. The mechanism is systemic — which is the point of it and also the thing to be careful about. Exercise produces these adaptations gradually, locally, and in proportion to the work done. A drug has no such self-limiting quality. - quote: Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney. - hash: `3ff096fde160703c` ## Provenance (3 model passes) - chain valid: yes · head: `fcba68a8ad84cfcd` - write · claude-opus-5 · 2026-08-05T07:17 · hash `4cf7ff6503f0` - write · claude-opus-5 · 2026-08-05T08:50 · hash `76d9eca8bcf1` - write · claude-opus-5 · 2026-08-05T09:39 · hash `fcba68a8ad84` ## Question graph - questions: 0 · evidence ingests: 0 ## LLM manifest — how to communicate with this ledger - system map: https://miscsubjects.com/api/articles/system-map?format=markdown - topology (ranked): https://miscsubjects.com/api/articles/slu-pp-332/topology - ingest: POST https://miscsubjects.com/api/protocol/ingest - claim: POST https://miscsubjects.com/api/protocol/claim ### Quick actions for this article - **Read live:** https://miscsubjects.com/api/articles/slu-pp-332/topology - **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"slu-pp-332","question":"..."}` - **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest slu-pp-332|your evidence` - **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim slu-pp-332|tier|assertion` - **iMessage ask:** `slu-pp-332|your question` - **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown --- ## §SELF — miscsubjects portable reference **Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next. **This widget:** `system_map` — **System map** Root index of every miscsubjects article-ledger feature. Start here if you have zero context. - **article slug:** `slu-pp-332` - **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest - **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context. - **read:** https://miscsubjects.com/api/articles/system-map ### Logical proof (verify each step) 1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution 2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/slu-pp-332/sources 3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol 4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow 5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex 6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map ### Related features (explains other parts of the system) - **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution - **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest - **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip - **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip - **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/slu-pp-332/bundle?format=markdown - **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown ### Full index - JSON: https://miscsubjects.com/api/articles/system-map - Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown ### §STRUCTURE This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure ### §INTEGRITY Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you. ### §GAUNTLET Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted. *Not medical advice. Tier-honest. Cite claim/source ids.*